Contact UsContact Us: (214) 386-7246(214) 386-7246

New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

The results of a study presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.

The results of a study presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.

Source: Science Daily

Read more

  • American Association of Neurological Surgeons
  • American Board of Neurological Surgery
  • American Medical Association
  • The Congress of Neurological Surgeons
  • College of Physicians and Surgeons of Newfoundland & Labrador
  • North American Skull Base Society
  • North American Spine Society